Showing 971-980 of 5062 results for "".
- Cynosure to Name Stephen J. Webber as New CFOhttps://practicaldermatology.com/news/cynosure-to-name-stephen-j-webber-as-new-cfo/2458436/Cynosure, Inc. announced that Stephen J. Webber will join the company on October 10, 2016 as Executive Vice President. Mr. Webber will then become Chief Financial Officer and Chief Accounting Officer effective upon the filing in Novembe
- Sensus Healthcare Receives Frost & Sullivan 2016 Global NMSC Therapy Technology Leadership Awardhttps://practicaldermatology.com/news/sensus-healthcare-inc-receives-frost-sullivan-2016-global-nmsc-therapy-technology-leadership-award/2458443/Sensus Healthcare, Inc. has been named the winner of the Frost & Sullivan 2016 Global Non-melanoma Skin Cancer Therapy Technology Leadership Award for its innovative therapy treatment technology. Sensus Healthcare scored an average 9.5 out of 10 possible points on the Frost & Sullivan Tec
- FDA Bans 19 Ingredients from Hand Soapshttps://practicaldermatology.com/news/fda-no-more-antibacterials-allowed-in-consumer-soaps/2458446/Antibacterial soaps will soon be gone from store shelves, according to a new rule from the US Food and Drug Administration (FDA). This
- FDA Approves Enbrel Biosimilarhttps://practicaldermatology.com/news/fda-approves-enbrel-biosimilar/2458451/The U.S. Food and Drug Administration (FDA) approved Erelzi for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. The move is no surprise given the unanimous backing of an FDA advisory arm last month. There are now
- It's So Far, So Good for BioPharmX's New Acne Drughttps://practicaldermatology.com/news/its-so-far-so-good-for-biopharmxs-new-acne-drug/2458458/BioPharmX Corporation’s novel topical minocycline, BPX-01, reduced facial P. acnes by more than 90 percent after four weeks, new research shows. In the Phase 2a study, a daily 10 mg dose of topical minocycline offered P. acnes r
- Valeant Dermatology ASPIRE HIGHER Scholarship Program Names Winnershttps://practicaldermatology.com/news/valeant-dermatology-aspire-higher-scholarship-program-names-winners/2458472/Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, announced the winners of its ASPIRE HIGHER Scholarship Program. Nine undergraduate and graduate students were selected from a pool of 970 applicants and awarded up to $10,000 each tow
- Summer 2016's Must-Have Accessory: La Roche-Posay's New UV Patch Available Nowhttps://practicaldermatology.com/news/summer-2016s-must-have-accessory-la-roche-posays-new-uv-patch-available-now/2458491/La Roche-Posay’s new UV patch monitor and companion app are here. My UV Patch measures UV exposure in real time. The water- and sweat-resistant patch can be used for up to three days during all outdoor activities. It is approximately one square inch and 50 micrometers thick &n
- Galderma and Chugai Announce Global License Agreement for Nemolizumab, Novel Biologic for Skin Diseaseshttps://practicaldermatology.com/news/galderma-and-chugai-announce-global-license-agreement-for-nemolizumab-novel-biologic-for-skin-diseases/2458496/Chugai Pharmaceutical Co., Ltd. and Galderma Pharma S.A. have entered into a global license agreement for nemolizumab (CIM331), the anti-IL-31 receptor A humanized monoclonal antibody created by Chugai, which is currently under development for atopic dermatitis and pruritus in hemodialysis patien
- North America's Scar Treatment Poised for Growth Spurt by 2022https://practicaldermatology.com/news/north-america-scar-treatment-market-set-to-grow-by-2022/2458629/Scar treatment will be a hot growth area in coming years, according to a new report by Persistence Market Research. The report cites a rising incidence of burn and trauma cases and an increasing preval
- Study Links Psoriasis to Bone Loss. Is IL-17 to Blame?https://practicaldermatology.com/news/study-links-psoriasis-to-bone-loss-is-il-17-to-blame/2458641/Psoriasis is linked to widespread bone loss, according to Researchers from the Genes, Development and Disease Group at the Spanish National Cancer Research Centre (CNIO) in Madrid. The new study, which appears in Sc